Should lipids be monitored during the first year of treatment with an atypical antipsychotic?
Landry
Pierre
P
Benaliouad
Faïza
F
D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D002784:Cholesterol / Q000097:blood; D003024:Clozapine / Q000009:adverse effects*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology*; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D012559:Schizophrenia / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood
D014150:Antipsychotic Agents; D014280:Triglycerides; D001569:Benzodiazepines; D010890:Pirenzepine; D002784:Cholesterol; D003024:Clozapine; D000077152:Olanzapine